PRO Update: RXRX—Artificial Intelligence Meets a Potential Trend ReversalSeptember 30, 2026 This morning’s Genomics Acceleration Screen brought Recursion Pharmaceuticals (RXRX) to our attention. A closer look revealed something more interesting than a short-term momentum trade: a stock challenging a major downtrend after months of building a base. I bought the January 15, 2027 $5 calls at $0.57. This is an early entry based on the hourly breakout, ahead of confirmation from the daily and weekly closes. Recursion uses artificial intelligence, automated laboratory experiments and proprietary biological data to identify and develop potential medicines. The business offers exposure to both biotechnology and AI—but the chart is what prompted this trade. The weekly picture The weekly chart shows the damage from a prolonged decline—and the beginnings of a possible recovery. Since July, rising lows have pushed price into the descending resistance line drawn from the early-2025 high. This week’s advance has penetrated that line. A weekly close above it would strengthen the case that this phase of the downtrend is ending. That confirmation remains pending. The longer-term resistance line overhead also reminds us that one breakout does not clear every obstacle. The daily picture The daily chart brings the immediate decision into focus. RXRX reached $4.29 this morning before pulling back to approximately $4.16 in the accompanying snapshot. The stock is testing the $4.10–$4.20 breakout area. A daily close above $4.20 would provide stronger evidence that buyers are overcoming both descending resistance and the recent highs. A subsequent move above $4.29 would add follow-through. If the breakout holds, $4.80–$5.20 is the first resistance zone I would watch. A sustained move through that area would be needed to develop the larger upside case. These are conditional objectives, not promises. A close back beneath the broken trendline, currently around $4.10, would put the breakout in question. Why the January $5 calls? The accompanying September 30 morning option snapshot shows: Zooming in on the January $5 Call: Contract Bid–ask Volume Open interest RXRX Jan. 15, 2027 $5 call $0.53–$0.54 1,134 39,956 January gives the setup approximately three and a half months to develop. The $5 strike combines a modest dollar commitment with a tight quoted spread and active trading. It is an aggressive selection: the stock must advance meaningfully, and time decay or falling implied volatility can work against us. My fill was $57 per contract, before fees. The later snapshot offers a lower quoted price; neither quote guarantees a fill. Use limit orders. Trade management Our initial −50% option exit rule applies. Once the option gains 100%, apply our standard trailing-profit discipline, with any eventual 10–20% “just in case” residual treated separately. Stops cannot guarantee execution prices. PRO trade: RXRX January 15, 2027 $5 calls. I am already positioned; subscribers who prefer confirmation can wait for a daily close above $4.20 and reassess the option price then.
